Amprius Technologies enters the week with a rare and uncomfortable alignment: insiders selling aggressively at the top, short sellers adding exposure on the way down, and the stock now 11% lower on the week.
The insider story is the most striking thread. The Chairman of the Board, Donald Dixon, sold 85,000 shares on June 15 alone — raising roughly $1.46 million at $17.17 — just days after an earlier 40,000-share sale on June 9 at $19.13 that netted another $765,000. CEO Tom Stepien added a smaller sale on June 4. The CTO and at least one director have also trimmed positions. Aggregate net selling across insiders over the past 90 days runs to roughly $33 million in value — a figure that's hard to dismiss as routine diversification. What makes it notable is the timing: Dixon was selling into a rally, then selling again as the stock rolled over, with AMPX now trading at $15.49 — well below the prices at which he was exiting.
Short sellers have taken note. Short interest climbed roughly 10.5% over the past week to reach 19.1% of the free float — nearly one in five freely traded shares is now borrowed and sold. That's a meaningful level for a company of this profile, and the direction of travel has been consistently higher for more than a month, with the short position up around 7.5% from a month ago. The ORTEX short score sits at 58.3, reflecting a modestly elevated short-selling risk signal. One contrarian note: availability is actually loosening rather than tightening, with the ratio of shares still available to borrow rising to 407% — meaning there is plenty of capacity for new shorts to enter without straining the lending market. Cost to borrow has eased to just 0.42%, near the low end of its recent range. The borrow market is relaxed even as the short position grows.
Options traders are leaning slightly more bullish than usual, which cuts against the bearish tape. The put/call ratio has drifted down to 0.63, about 1.5 standard deviations below its 20-day average of 0.67 — a modest but real shift away from hedging demand. That divergence from the short interest trend is worth flagging: options flow is not confirming the bearish thesis, even as short sellers build.
On the Street, the analyst picture is uniformly constructive — perhaps unusually so. Clear Street initiated coverage with a Buy and a $33 target as recently as June 3, the most recent formal action. Earlier in March, B. Riley, Craig-Hallum, and Cantor Fitzgerald all raised targets, landing in the $20–$22 range. The consensus mean price target of roughly $22 implies around 42% upside from current levels. Bulls point to 93 customers last quarter including 43 new additions, operating losses shrinking from $12.9 million to $6.8 million, and management's projection of 25–27% margins by 2028. Bears note the company still prints a net loss every quarter, and the EV/EBITDA multiple — even after compressing roughly 37 points over the past 30 days — remains stratospheric at 163x, a figure that reflects how much execution risk is still embedded in the valuation. The EPS momentum factor ranks in just the 1st and 2nd percentile on both 30- and 90-day timeframes, though EPS surprise ranks in the 94th — the company has beaten low expectations, even if the direction of forward estimates has been weak.
One recent earnings print provides useful context. The last formal print on May 7 sent the stock down 24.7% in a single session and 19.5% over the following five days. The next earnings event is scheduled for August 6 — still seven weeks away, but the scale of that prior reaction illustrates how volatile these prints can be for a pre-profitability growth name with a large short base.
The stock to watch into August is how the insider selling pace evolves against the short interest build — whether Dixon and other senior holders continue to reduce at lower prices will say something about their own conviction in the $33 analyst target pinned to this stock just two weeks ago.
See the live data behind this article on ORTEX.
Open AMPX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
